Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...
The Progressive Corporation has reported its financial results for October, showing increases in several segments compared to the prior-year period. Net premiums written for the month reached $7.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback